Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

CARMIEL, Israel, May 23, 2017 -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF) and including new clinical data will be given at the 40th European Cystic Fibrosis Society Conference which is being held June 7-10, 2017 in Seville, Spain.

The oral presentation, titled “Phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis,” will be given by Professor Eitan Kerem, Head of the Division of Pediatrics, Children’s Hospital, Hadassah Medical Center, and principal investigator of the clinical trial on Wednesday, June 7 from 3:00pm to 4:30pm CET as a part of a workshop titled, “The airway surface, mucus and inflammation – new treatments.”  An archived copy of the presentation will be available following the conference at www.protalix.com on the presentations tab of the investor page.

Alidornase alfa is a plant cell-expressed, chemically-modified recombinant DNase enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzyme’s efficacy in CF patients.  Sixteen patients enrolled and completed the phase II clinical trial. 

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®.  Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.  Protalix’s development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-106, an orally delivered anti-inflammatory treatment; PRX-110, a chemically modified DNase I for the treatment of Cystic Fibrosis; and others.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  The terms “anticipate,” “believe,” “estimate,” “expect,” “plan” and “intend” and other words or phrases of similar import are intended to identify forward-looking statements.  These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause material differences are described in our filings with the U.S. Securities and Exchange Commission.  The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.

Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2952
[email protected]